News
TVGN
7.34
+0.14%
0.01
Weekly Report: what happened at TVGN last week (0831-0904)?
Weekly Report · 2d ago
Weekly Report: what happened at TVGN last week (0824-0828)?
Weekly Report · 08/31 10:28
Tevogen Bio Shareholders Approve Governance-Enhancing Charter Changes
TipRanks · 08/26 19:27
Weekly Report: what happened at TVGN last week (0817-0821)?
Weekly Report · 08/24 10:29
Weekly Report: what happened at TVGN last week (0810-0814)?
Weekly Report · 08/17 10:30
Weekly Report: what happened at TVGN last week (0803-0807)?
Weekly Report · 08/10 10:24
Weekly Report: what happened at TVGN last week (0727-0731)?
Weekly Report · 08/03 10:24
Tevogen Bio Holdings Rebrands as Tevogen Inc.
TipRanks · 07/30 12:57
Tevogen Bio becomes Tevogen Inc.
Seeking Alpha · 07/29 13:12
Tevogen To Operate Under Tevogen Inc. Name, Effective July 30
Benzinga · 07/29 12:03
*Tevogen Bio Holdings to Change Name to Tevogen
Dow Jones · 07/29 12:02
Top Biotech Gainers: GOSS To File Seralutinib NDA In Sep, OMER Gains On AZN's Loss, FBRX Acquired
NASDAQ · 07/28 03:29
Weekly Report: what happened at TVGN last week (0720-0724)?
Weekly Report · 07/27 10:29
Weekly Report: what happened at TVGN last week (0713-0717)?
Weekly Report · 07/20 10:25
Press Release: Tevogen Bio Announces 2026 Annual Meeting of Stockholders
Dow Jones · 07/14 02:15
Tevogen Bio Announces 2026 Annual Meeting of Stockholders
Barchart · 07/13 21:15
Weekly Report: what happened at TVGN last week (0706-0710)?
Weekly Report · 07/13 10:27
Weekly Report: what happened at TVGN last week (0629-0703)?
Weekly Report · 07/06 10:31
12 Health Care Stocks Moving In Monday's Pre-Market Session
Benzinga · 06/29 12:05
Weekly Report: what happened at TVGN last week (0622-0626)?
Weekly Report · 06/29 10:25
More
Webull provides a variety of real-time TVGN stock news. You can receive the latest news about TEVOGEN INC through multiple platforms. This information may help you make smarter investment decisions.
About TVGN
Tevogen Inc., formerly Tevogen Bio Holdings Inc., is a socially integrated healthcare enterprise. The Company leverages artificial intelligence and precision T cell therapy platforms, and engagements with global technology companies to support the development of advanced, life-saving therapies across multiple therapeutic areas and scalable solutions for the broader healthcare system. Tevogen Bio, its lead initiative, has completed a proof-of-concept clinical trial demonstrating the potential of its single-HLA-restricted, genetically unmodified allogeneic T cells. Tevogen Bio's pipeline spans virology, oncology, and neurology. Tevogen.AI is designed to transform drug development by accelerating target detection, helping reduce failure rates, and supporting optimized clinical trial design through proprietary predictive technologies. It is exploring strategic initiatives that may include domestic generics, biosimilars, medical devices, and insurance solutions for healthcare providers.